FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella
The FcRn-targeted strategy establishes concurrent mucosal and systemic protective immunity against <i>Brucella</i> infection. This novel vaccine candidate shows potential for effective human brucellosis prevention, offering a promising approach to address the limitations of current vaccines.
Authors
- Fengbo Zhang (ORCID: https://orcid.org/0000-0001-5795-8672)
- Yuejie Zhu (ORCID: https://orcid.org/0000-0002-6088-8991)
- Fangfang Pu
- Jianbing Ding (ORCID: https://orcid.org/0000-0001-5506-7665)
- Huidong Shi (ORCID: https://orcid.org/0000-0003-1137-3390)
- Tingting Tian (ORCID: https://orcid.org/0000-0001-8767-091X)
- Junyu Kuang
- Rui–Xue Xu (ORCID: https://orcid.org/0000-0001-9931-201X)
- Mingzhe Li (ORCID: https://orcid.org/0000-0001-8382-0028)
- Kaiyu Shang
Institutions
- Xinjiang Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2025-05-26
- DOI
- https://doi.org/10.3390/vaccines13060567
- Citations
- 1
- Primary Topic
- Brucella: diagnosis, epidemiology, treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.35
Funders
- National Natural Science Foundation of China
- Xinjiang Medical University